HIV and Cardiovascular Disease: A Growing Concern

For individuals living with human immunodeficiency virus (HIV), the landscape of health concerns extends beyond immune function. Cardiovascular disease (CVD) has emerged as a significant and growing threat, impacting the health and longevity of those with HIV, even with advancements in antiretroviral therapy (ART). This article explores the complex relationship between HIV and CVD, the underlying mechanisms and current strategies for prevention and management.

The Link Between HIV and Cardiovascular Disease

Studies consistently demonstrate a higher prevalence of cardiovascular complications in people living with HIV compared to their uninfected counterparts [1]. These complications encompass a range of conditions, including pericardial effusion, myocarditis, dilated cardiomyopathy, and accelerated atherosclerosis [3]. Whereas the introduction of ART has dramatically improved immune function and overall survival, it hasn’t fully eliminated the increased risk of CVD [1].

Underlying Mechanisms

The increased risk of CVD in HIV infection is multifactorial, stemming from both direct and indirect effects of the virus and its treatment. Several key mechanisms are believed to contribute:

• Immune Activation and Inflammation: HIV infection is characterized by chronic immune activation, even in individuals on effective ART. This persistent inflammation contributes to endothelial dysfunction, a critical early step in the development of atherosclerosis.
• Viral Proteins: HIV proteins themselves may directly damage the cardiovascular system.
• Lipid Abnormalities: ART, particularly older regimens, can sometimes lead to dyslipidemia (abnormal blood lipid levels), increasing the risk of atherosclerosis.
• Endothelial Dysfunction: Impairment of the endothelium, the inner lining of blood vessels, is common in HIV infection and contributes to vascular disease.

Cardiac Manifestations of HIV

The specific ways HIV impacts the heart are varied:

• Pericardial Effusion: An accumulation of fluid around the heart, often an early manifestation of HIV infection.
• Myocarditis: Inflammation of the heart muscle.
• Dilated Cardiomyopathy: A condition where the heart chambers enlarge and weaken, reducing the heart’s ability to pump effectively.
• Accelerated Atherosclerosis: The buildup of plaque in the arteries, leading to coronary artery disease, heart attack, and stroke.

Prevention and Management

Managing cardiovascular risk in people living with HIV requires a comprehensive approach:

• Antiretroviral Therapy (ART): Initiating and adhering to ART is paramount. Effective viral suppression reduces immune activation and inflammation, lowering CVD risk [1].
• Lifestyle Modifications: Adopting a heart-healthy lifestyle, including a balanced diet, regular exercise, and smoking cessation, is crucial.
• Lipid Management: Regular monitoring of lipid levels and, when necessary, treatment with statins to lower LDL cholesterol. Recent research suggests statins may also reduce immune activation and inflammation in people with HIV [4].
• Blood Pressure Control: Managing hypertension (high blood pressure) is essential.
• Regular Monitoring: Routine cardiovascular screening, including blood pressure checks, lipid profiles, and electrocardiograms, is recommended.

The Future of HIV and CVD Research

Ongoing research continues to refine our understanding of the complex interplay between HIV and CVD. Studies are investigating novel therapeutic strategies to target inflammation and improve vascular health in people living with HIV. Tracking the incidence and course of HIV infection in relation to cardiac illness remains a priority [2].

As ART continues to extend the lifespan of individuals with HIV, addressing cardiovascular health will become increasingly important for ensuring long-term well-being.